Gilead Sciences on Thursday reported a first-quarter profit, but revenue was flat, as higher sales of drugs for HIV and liver ...

Lenacapavir could be a gamechanger in the fight against infection. But US funding cuts have thrown the rollout of the ...

In a first-ever milestone, Africa’s initial HIV cure trial has yielded historic findings: 20% of patients have remained off ...

In the face of a fear of loss of funds for ending the HIV/AIDS epidemic, activists in New Jersey walked to raise money.

After counsel withdrew for some of the plaintiffs in a huge consolidated legal battle between Gilead Sciences and patients ...

The company paid to settle allegations of paying kickbacks to doctors in exchange for prescribing several of its HIV ...

On April 22, the CDC allegedly informed Emory University in Atlanta that its large HIV self-testing program was being ...

Moving misbranded and adulterated HIV drugs from the black market to retail pharmacies and HIV patients was a $60 million ...

Exclusive: World Health Organisation says shortage of most commonly used Aids drug caused by withdrawal of US foreign aid ...

Seven percent of 108 healthy volunteers reported urticaria; unresolved urticaria persisted at 12 months in four participants.